Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Inhibrx Biosciences, Inc. (INBX) had Free Cash Flow of $-99.70M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-35.26M |
|
-- |
|
-- |
|
$33.81M |
|
$-33.81M |
|
$-1.44M |
|
$-35.26M |
|
$-35.26M |
|
$-35.26M |
|
$-35.26M |
|
$-35.26M |
|
$-35.26M |
|
$-33.81M |
|
$-33.23M |
|
15.48M |
|
15.48M |
|
$-2.28 |
|
$-2.28 |
|
| Balance Sheet Financials | |
$161.42M |
|
$4.31M |
|
$16.05M |
|
$177.47M |
|
$35.98M |
|
$99.92M |
|
$104.66M |
|
$140.64M |
|
$36.83M |
|
$36.83M |
|
$36.83M |
|
14.50M |
|
| Cash Flow Statement Financials | |
$-99.67M |
|
$-0.03M |
|
$100.19M |
|
$152.60M |
|
$153.09M |
|
$0.49M |
|
$8.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.49 |
|
-- |
|
-- |
|
0.73 |
|
2.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-99.70M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-95.73% |
|
-95.73% |
|
-19.87% |
|
-25.78% |
|
$2.54 |
|
$-6.44 |
|
$-6.44 |
|